Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founder & CEO, of Mydecine Innovations Group, Josh Bartch.
Similar Posts
Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!
Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain
Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793
Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080
FDA Greenlights Ketamine:
https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/
California Bill to Decriminalize Psychedelics Passes Senate Floor:
https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #PsychedelicIndustry
Interview with Dr. Erica Zelfand
This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
Interview With James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature James Hallifax, Co-Founder of The Psychedelic Investor.
Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT
In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).
Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting.
Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.
Excitingly, Mindset is moving towards beginning clinical trials in 2022.
On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs.
In the long term, this deal has great potential for Otsuka.
To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:
Can psychedelics treat mental illnesses such as depression?
Are next-generation psychedelics better than the originals?
What is happening in the brain when a person takes psychedelics?
Enjoy the episode!
You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.
*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/
#MindsetPharma #DMT #microdosing
Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
Amanita Muscaria and Desert Herbalism with Ash Ritter
We dive into the world of the infamous Amanita Muscaria mushroom and learn about the wild desert apothecary of fungi and herbs.